Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $89.95 USD
Change Today -0.01 / -0.01%
Volume 13.1M
HSP On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

hospira inc (HSP) Snapshot

Open
$89.96
Previous Close
$89.96
Day High
$89.98
Day Low
$89.95
52 Week High
08/18/15 - $90.63
52 Week Low
10/15/14 - $46.56
Market Cap
15.6B
Average Volume 10 Days
5.0M
EPS TTM
$2.59
Shares Outstanding
172.9M
EX-Date
--
P/E TM
34.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for HOSPIRA INC (HSP)

hospira inc (HSP) Details

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprise Biosimilars that include Retacrit, an EPO, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of patients with autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a nonsteroidal anti-inflammatory drug analgesic. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

19,000 Employees
Last Reported Date: 02/12/15
Founded in 2003

hospira inc (HSP) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $477.4K
Senior Vice President of Operations
Total Annual Compensation: $464.7K
President of Hospira Medical Devices
Total Annual Compensation: $512.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $550.5K
Compensation as of Fiscal Year 2014.

hospira inc (HSP) Key Developments

Hospira, Inc. Announces First Installation of Plum 360 Infusion System with Hospira Mednet

Hospira Inc. announced the first installation of the Plum 360™ infusion system with Hospira MedNet™, at Shannon Medical Center in San Angelo, Texas. The Plum 360 infusion system, supported by the new Hospira MedNet version 6.1 safety software, is the latest addition to Hospira's innovative portfolio of next-generation smart pumps. The Plum 360 infusion system includes unique features designed to address challenges that hospitals face daily as they work to improve the safety of intravenous (I.V.) medication administration. These include a secondary line that connects directly to the PlumSet™ cassette, enabling the pump to be programmed with two compatible medications in either concurrent or piggyback delivery. The secondary line, delivered through channel B of the pump, also integrates with the electronic medical record (EMR) systems through Hospira's I.V.-EMR interoperability solution. The secondary line enables air management that does not require disconnecting the line from the patient, which helps reduce the potential for contamination. Hospira MedNet further enhances the safety features of the Plum 360 infusion system with an expanded drug library to support safety limits for more medications, across more clinical care areas of use, helping to enhance clinical best practices for I.V. medication administration. The Plum 360 infusion system also provides several security enhancements, including improved protection of critical communication ports, no remote command execution, and support for 128-bit SSL encryption of all data transmitted to and from Hospira MedNet version 6.1. The Plum 360 infusion system with Hospira MedNet is a complementary addition to Hospira's medication management portfolio, which also includes the new Sapphire™ ambulatory infusion system and the market-leading LifeCare PCA™ pain management pump with Hospira MedNet.

Hospira Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Hospira Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net sales of $1,183.6 million against $1,135.8 million a year ago. Income from operations was $218.6 million against $99.5 million a year ago. Income before income taxes was $206.0 million against $81.1 million a year ago. Net income was $145.1 million against $70.9 million a year ago. Earnings per share diluted were $0.82 against $0.42 per share a year ago. Adjusted net income from operations was $226.9 million against $179.3 million a year ago. Adjusted net income was $150.2 million against $122.1 million a year ago. Adjusted diluted earnings per share were $0.85 against $0.72 per share a year ago. For the six months, the company reported net sales of $2,358.5 million against $2,186.6 million a year ago. Income from operations was $352.0 million against $199.1 million a year ago. Income before income taxes was $327.9 million against $162.2 million a year ago. Net income was $220.7 million against $138.8 million a year ago. Earnings per share diluted were $1.26 against $0.82 per share a year ago. Adjusted net income from operations was $474.1 million against $330.8 million a year ago. Adjusted net income was $320.3 million against $223.8 million a year ago. Adjusted diluted earnings per share were $1.82 against $1.32 per share a year ago. Net cash provided by operating activities was $186.2 million against $175.5 million a year ago. Capital expenditures was $221.4 million against $184.8 million a year ago.

Hospira Launches of Generic Bivalirudin for Injection

Hospira announced that it had obtained U.S. Food and Drug Administration approval for the launch of bivalirudin for injection, a generic version of The Medicines Company's Angiomax. Hospira's bivalirudin for injection is available in a single-dose flip-top vial, which matches the current branded offering available. Additionally, the company plans to launch a differentiated presentation of the 250 mg bivalirudin for injection in Hospira's unique ADD-Vantage vial. Hospira's bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA); patients undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor (GPI); and patients with, or at risk of, heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS), undergoing PCI. Bivalirudin is intended for use with aspirin.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSP:US $89.95 USD -0.01

HSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chugai Pharmaceutical Co Ltd ¥4,295 JPY -55.00
Cintas Corp $84.62 USD +1.56
Endo International PLC $74.96 USD +1.48
UCB SA €70.94 EUR +1.50
Zimmer Biomet Holdings Inc $101.63 USD +0.98
View Industry Companies
 

Industry Analysis

HSP

Industry Average

Valuation HSP Industry Range
Price/Earnings 37.6x
Price/Sales 3.4x
Price/Book 4.3x
Price/Cash Flow 37.5x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOSPIRA INC, please visit www.hospira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.